Checkpoint Inhibitors Under Exploration in RCC

For High-Definition, Click

There are several early phase clinical trials assessing PD-1 inhibitors for patients with renal cell carcinoma, notes Nicholas J. Vogelzang, MD. At this point, a clear leader has not yet emerged. Genentech is currently exploring bevacizumab plus their PD-L1 inhibitor MPDL3280A. Additionally, BMS has an advantage by marketing both nivolumab and ipilimumab. With all of the agents under exploration, it is a good time for referring patients to clinical trials, Vogelzang adds.